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Summary 
Background: Problem of the variability between the
different methods using for bone alkaline phosphatase
(bALP) determination greately influences the clinical
significance of bALP as direct marker of bone metabolism.
The aim of this study was to compare immunoassay with
electrophoresis technique for bALP determination.  
Methods: We measured bALP in 71 patients on hemo -
dialysis with agar gel electrophoresis (ISO-PAL, SEBIA) and
immunoassay (OSTASE, Beckman Coulter).
Results: The analyzed methods showed significant
correlation (Spearman’s rho: 0.776, P < 0.01), but we
found statistically significant (P < 0.01) positive bias (27%)
for the results measured by immunoassay. In support of
this, using electrophoresis technique we have detected
presence of the intestinal isoenzymes of alkaline phos-
phatase in 55% of patients with median value of 30% of the
total alkaline phoshatase and presence of liver-2 alkaline
phosphatase isoform in 42% of patients with median value
of 16.6%. The Kendall’s W of 0.787 (P<0.0001) revealed
significant concordance between two analysed methods.
Cusum test showed no significant deviation from linearity
(P=0.850).
Conclusions: Despite good agreement between immuno -
assay methods and electrophoresis technique for bALP
determination, interchangeability between these two
methods is questionable. Although immunoassays are
increasingly used, as fully automated methods, in a large
Kratak sadr`aj
Uvod: Problem varijabilnosti izme|u razli~itih metoda
pomo}u kojih se odre|uje ko{tani izoezim alkalne fosfataze
(bALP) u velikoj meri uti~e na klini~ki zna~aj bALP kao
direktnog markera metabolizma kostiju. Cilj ove studije bio
je pore|enje imunohemijskog testa sa elektroforetskom
tehnikom za odre|ivanje bALP.
Metode: bALP je odre|en kod 71 pacijenta na hemodijalizi,
agar gel elektroforetskom tehnikom (ISO-PAL, SEBIA) i
imunohemijskom metodom (OSTASE, Beckman Coulter).
Rezultati: Analizirane metode pokazale su zna~ajno
slaganje (Spearmanov rho: 0,776, P < 0,01), ali je uo~en
statisti~ki zna~ajan (P < 0,01) pozitivan bias (27%) za
rezultate izmerene imunohemijskom metodom. U prilog
ovome, primenom elektroforetske tehnike, otkrili smo
prisustvo intestinalnih izoenzima alkalne fosfataze u 55%
bolesnika, sa srednjom vrednosti od 30% ukupne alkalne
fostataze, kao i prisustvo jetrenih izoformi alkalne fosfataze
kod 42% bolesnika sa srednjom vrednosti od 16,6%.
Kendall-ov W od 0,787 (P < 0,0001) ukazivao je na
zna~ajno slaganje izme|u dve analizirane metode.
Cusumov test nije pokazao zna~ajno odstupanje od
linearnosti (P  = 0,850).
Zaklju~ak: Uprkos tome {to postoji dobro slaganje izme|u
imunohemijske metode i elektroforetske tehnike za
odre|ivanje bALP-a, me|usobna zamenjivost ove dve
metode je pod znakom pitanja. Iako se imunohemijske
metode sve vi{e koriste kao potpuno automatizovane, u
List of abbreviations: bALP, bone alkaline phosphatase; HD,
hemodialysis; PTH, parathyroid hormone; IQR, interquartile
range; CI, confidence interval; RSD, residual standard
deviation
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Introduction
Bone alkaline phosphatase isoenzyme (bALP) is
considered a useful biomarker for assessing the level
of bone metabolism in patients on dialysis (1). In spite
of the fact that it directly depicts the bone formation
cells metabolism and is present in the guidelines as a
recommended biomarker, it has not yet been fully
implemented in practice. The basic problem is that
there is no harmonization of the methods used to
determine this isoenzyme, and there is no agreement
between the recommended cut-off values  in the
estimation of bone metabolism levels. Various studies
that examined the relationship between biomarkers
and bone histology in patients on hemodialysis (HD)
have not agreed in proper bALP cut-off value for
difference between low, normal and high bone
turnover (2, 3). In addition to the different
methodology used, the heterogeneity of histological
abnormalities in HD patients is also a problem (3).
Originally used electrophoretic methods were not
easily feasible and practically applicable as a routine
in most laboratories. The development of automation
and application of immunochemical methods in
routine practice has made it easier to determine bALP.
However, immunochemical determination is subject
to numerous interferences, different specificity of the
antibodies used for detection, and method stan -
dardization problems (4).
It is considered that the associated determina-
tion of bALP and parathyroid hormone (PTH) does
not increase the diagnostic capability of PTH as a rec-
ommended biomarker to distinguish between low,
normal and high bone turnover (3). Also, the litera-
ture data indicate that there is a discrepancy between
the levels of bALP and PTH, although in most cases
bALP determination correlates with PTH in estimat-
ing the level of bone metabolism (5–7). However, the
benefit of bALP lies in the fact that this isoenzyme is
a direct product of bone metabolism, while PTH as a
biomarker reflects parathyroid activity and is only an
indirect indicator of bone metabolism. Also, the
determination of bALP has several advantages from
the analytical aspect: better stability, better analytical
and intra-individual coefficient of variation (2).
Although the cut-off values for bALP in bone
metabolism assessment depend on the method of
determination, the initially recommended values of
bALP specific electrophoretic technique were 27 U/L
with 84% sensitivity and 70% specificity, with 90%
positive predictability for high bone turnover and 58%
positive predictability for low bone turnover (8–11).
Cut-off value of 53 U/L had 100% specificity and
100% sensitivity, with 84% positive predictability for
high bone turnover and 100% positive predictability
for low bone turnover (8–11).
The aim of this study was to compare bALP
values determined by the electrophoresis technique
and immunochemical method in patients on dialysis
in order to examine the agreement between these
two methods and the impact on the appropriate
assesments of bone metabolism in these patients




This study was conducted in 2015, and it
included 71 patients (mean age: 56 ± 14.6, 44 years
old, 44 males) undergoing maintenance hemodialysis
(duration: 5 years and 17 months). All patients were
treated at the Clinic of Nephrology, Clinical Center of
Serbia. Prior to the study all the patients agreed to
participate and gave their informed consent. Blood
samples were drawn immediately prior to dialysis
session and centrifugated within an hour. We con -
stituted aliquots of samples and froze them at -70 °C
until determination within the next two months.
Practical work was conducted at the Laboratory for
Medical Biochemistry Analysis, Faculty of Pharmacy,
University of Belgrade and the Center of Medical
Biochemistry, Clinical Center of Serbia. All patients
gave informed consent to participate in the study,
which was conducted according to the Helsinki
Declaration and approved by the Ethics Committee of
the Clinical Center of Serbia.
Methods
We determined bALP activity using commercial
kits for agarose gel electrophoresis technique
(HYDRAGEL 7 and 15 ISO-PAL gels) on Hydrasis
semi-automatic electrophoresis system (ISO-PAL,
Sebia, France). Isoforms of total alkaline phosphatase
were identified after sample migration in duplicate,
using lectin for precipitation of bone isoenzime in one
track, and quantified using specific chromogenic
substrate. The value of bone isoenzyme is obtained by
subtracting the densitometric values of liver-1 and
placental-1 fractions obtained from the lectin track,
from the value of the sum of liver-1, bone and
number of laboratories and become routine methods for
bALP determination, it should be beared in mind, besides
various interferences, also the heterogeneity of the bALP
itself, especially in patients on hemodialysis.
Keywords: bone alkaline phosphatase, electrophoresis,
hemodialysis, immunoassay 
velikom broju laboratorija i postaju rutinske metode za
odre|ivanje bALP-a, treba imati na umu, osim razli~itih
interferencija, i heterogenost samog bALP, posebno kod
bolesnika na hemodijalizi.
Klju~ne re~i: ko{tana alkalna fosfataza, elektroforeza,
hemodijaliza, imunoodre|ivanje
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placental-1 fraction of the »without« lectin track. All
other fractions, liver-2, three separated intestinal
fractions, placental-2 and the lipo complex are
determined on the track without lectin. We used
commercial quality control material, wich contains a
human serum pool with alkaline phosphatase
isoenzymes, as internal quality control (ISO-PAL
Control (PN 4793), Sebia, France). Percentage on
HYDRAGEL 7 and 15 ISO-PAL for liver-1+bone
izoenzymes is 75.4% ± 7.8. Manufacturer’s recom -
mendation is to include one track of ISO-PAL Control
into each run on Hydragels (on CTL track) without
any lectin solution. According to the Manufacturer’s
performance specification analytical sensitivity is 2–3
U/L, dynamic range 50–600 U/L and within and
between gels coeficient of variation is < 6.5% and <
4.1%, respectively. ISO-PAL electrophoresis technique
was chosen as a comparative method.
bALP concentrations were also measured using
commercial one-step immunoenzymatic Access
OSTASE chemiluminiscence immunoassay (CLIA)
(Access OSTASE, Beckman Coulter, Inc.). In this
immunoassay, mouse monoclonal antibody specific
to bALP was added to a reaction vessel with
paramagnetic particles coated with goat anti-mouse
polyclonal antibody and chemiluminiscence of the
solid phase/capture antibody/bALP complex was
measured after adding supstrate Lumi-Phos* 530.
We used commercial quality control material (Access
OSTASE QC, Beckman Coulter, Inc.), level 1 and 2
(human bALP at a level of approximately 29.3 and
120 U/L in matrix buffered bovine serum albumin
with surfactant). We tested quality control specimens
with each analytical run. According to the Manu -
facturer’s performance specification analytical
sensitivity is 0.1 U/L, dynamic range 0.1–120 U/L
and imprecision 4.8% and 5.3% for low and high
internal quality control, respectively.
Reffering to a liver isoenzyme reactivity,
Manufacturer suggests that 100 U/L of bALP activity
yields a result of 37.5 U/L in the Access OSTASE
assay. We used this conversion factor to uniform units
of bALP measurement with two different methods
and express all results as acivities (U/L) (12).
Statistics
We have checked normality of the distribution
for the analyzed data using Kolmogorov–Smirnov test
and for subgroups with data number less than 50 we
used Shapiro–Wilkins test. We presented results as
median and interquartile range (IQR). We used
Passing–Bablock regression to assess the relationship
between bALP values measured with two different
assays. To additionally estimate agreement between
two methods we have determined Concordance
correlation coefficient for nonparametric data
(Kendall’s W). Bias in regression (Passing–Bablok
analysis) and the Spearman correlation coefficient
(Spearman’s rho) was calculated to estimate
relationship between continuous variables. The
constant bias between analysed assays was evaluated
from the intercept of the Passing–Bablok regression
line, and the proportional bias was evaluated from the
slope of the regression line. We have also determined
residual standard deviation (RSD) ± 1.96 RSD
interval as a marker of random differences, and
conducted Cusum test to check linearity of the
relationship between two data sets. In cases in which
the Spearman’s rho indicated poor correlation
between two assays (R2 < 0.500), Kendall’s W was
not considered relevant to estimate agreement. If the
correlation coefficient was substantial (R2 > 0.500),
the Kendall’s concordance correlation was evaluated.
The linear correlation coefficient R provides a
measure of linear relation between two sets of scores
without specifying any degree of correspondence
between the two sets of values. On the other hand,
the Kendall’s W provides a measure of reliability that
is based on covariation and correspondence and has
smaller gross error sensitivity (i.e. more robust) and a
smaller asymptotic variance (i.e. more efficient). All
statistical analysis were performed using MedCalc
Software bvba (Version 2.5.0.0., Ostend, Belgium)
and IBM SPSS Statistics version 21.0 (Chicago, IL). 
Results
Using electrophoresis technique, we found that
the median bALP concentration in all the analyzed
patients was 21.2 U/L (IQR: 11.1–39.5 U/L) and
ranged from 1.7–128.3 U/L. Using Access OSTASE
method, the converted median bALP concentration
into the same units as ISO-PAL was 37.4 U/L (IQR:
23.9–62.3 U/L) and ranged from 10.1–236.3 U/L.
The distribution of the results according to the used
Figure I Distribution of bALP concentrations determined in
71 hemodialyzed patients regarding the used electrophoresis
technique (bALP, U/L) and immunoassay method (OSTASE,
U/L). The solid line represent median value and first quartile
range.
method is presented in Figure 1. Using electro -
phoresis technique we have detected presence of the
intestinal isoenzymes of alkaline phosphatase in 55%
of patients with median value of 30% (IQR: 21.7–
43.1%) (Manufacturer recommendation for cut-off
for these izoenzymes is < 14%). In addition, we have
detected presence of liver-2 alkaline phosphatase
isoform in 42% of patients with median value of
16.6% (IQR: 11.8–22.4%) (Manufacturer recom -
mendation for cut-off for this isoform is < 9%).   
Passing–Bablock regression is presented in
Figure 2. with specified equation of the regression
line between the analyzed methods: y=5.87+1.44x
(R2=0.610). 95% confidence interval (CI) for syste -
matic differences was -0.64–10.39, for proportional
differences was 1.25–1.68, and for random diffe -
rences ± 1.96 RSD interval was -28.24–28.24. We
presented Passing-Bablok regression residuals plot in
Figure 3. that is a measure of random differences
between the analyzed methods, with RSD of 14.41.
The analyzed methods showed significant correlation
(Spearman’s rho: 0.776, P<0.01), but we found
statistically significant (P<0.01) positive bias (27%)
for the results measured by Access OSTASE
compared with those obtained with ISO-PAL. The
Kendall’s W of 0.787 (P<0.0001) revealed signifi -
cant concordance between two analysed methods.
Cusum test showed no significant deviation from
linearity (P=0.850).
According to the ISO-PAL, 59.2%, 30.9% and
9.9% of the patients presented bALP concentrations
≤ 27 U/L, between 27 and 53 U/L, and  53 U/L,
respectively. Using the regression equation, we
calculated equivalent concentrations obtained with
two methods, when the value measured with the
ISO-PAL is 27 and 53 U/L, that we presented in the
Table I. In addition, in the Table I we presented
Spearman’s rho and Kendall’s W between ISO-PAL
and Access OSTASE to classify the patients
accordingly.
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Table I Equivalent concentrations obtained with Access Ostase, when the value measured with the ISO-PAL is 27 U/L and 53
U/L, Spearman’s rho coefficient of correlation and Kendall s W coefficient of concordance between the analyzed methods to clas-
sify identically the patients when they present values ≤ 27 U/L, between 27 and 53 U/L, and ≥ 53 U/L with the ISO-PAL..
ISO-PAL bALP 
concentrations






 27 U/L (N=42)  44.75 U/L 0.598 (P < 0.001) 1.000 (P < 0.001)
27–53 U/L (N=22) 44.75–82.19 U/L 0.616 (P = 0.002) 0.669 (P < 0.001)
 53 U/L (N=7)  82.19 U/L 0.429 (P = 0.337) N/A
Figure II Passing-Bablock graphic present linear relation-
ship between the two different methods used to determine
concentrations of bone isoenzyme of alkaline phosphatase
(electrophoresis technique, bALP, U/L and immunoassay
method, OSTASE, U/L). Three different dot shapes and
colours present three subgroups of measured isoenzyme
concentrations according to the specified cut-off values of
< 27 U/L, 27–53 U/L and ≥ 53 U/L for low, normal and
high bone turnover, respectively.
Figure III Passing-Bablok regression residuals plot present
random differences between two analyzed methods regard-
ing the three subgroups according to the specified cut-off val-
ues for low, normal and high bone turnover.
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Discussion
Electrophoresis technique is used as a screening
method to assess relative part of bone isoenzyme
regarding the total alkaline phosphatase activity, while
using the immunochemistry assay it is possible to
measure the exact bone isoenzyme concentration.
Although these two methods have different
measuring principles, the obtained comparison
parameters in this study present good agreement
between two independent methods for bALP
determination, after we have conversed measured
concentrations to the same units. Although, so far,
there are not many published studies analyzing the
comparison of the electrophoretic and immuno -
chemical method of bALP determination, the
literature data generally indicate an inappropriate
agreement between the methods (2, 4, 6). In
addition, data analyses and interpretation is
complicated issue that has been discussed for
decades and still there is no gold standard for
statistical procedure that should be used for method
comparison data analyses (13). Also, there are
various interpretations of the matching coefficients
and statistical tests in general. In addition to the
different measurement principles of two analyzed
methods, disagreement can be a result of different
units of activity expression, i.e. concentrations of
bALP. So far, there are no generally accepted
recommendations for the conversion of activity units
into bALP units, which makes the values of this
isoenzyme significantly different between these two
methods. However, disagreement most likely lies in
the significant interference of other alkaline
phosphatase isoenzymes that impede with the
accurate and precise determination of the bALP using
the immunochemical method, as well as the
specificity of the detection antibodies. The obtained
data in our study, indicate a significant presence of
intestinal isoforms and liver-2 isoenzymes, which
most likely contribute to higher values of detected
bALP by the immunochemical method compared to
electrophoretic technique. This support findings of
Zhan et al. who pointed out that the accuracy of
electrophoresis was comparable to that of immuno -
chemistry assay when percent of serum bALP levels
were high in patients with liver disease, but that
accuracy of electrophoresis, further needs to be
assessed, with patient samples under certain disease
and conditions (14). 
Opposite to the study of Ahmed et al. (4), our
results indicate a significant positive bias of 27% for
concentrations measured by the immunochemical
method, which can be explained by the presence of
isoforms of other isoenzymes of total alkaline
phosphatase, that have been detected as bALP in
immunoassay. In cited study, analyzed patients had
Paget’s disease, and there was no significant
agreement between the electrophoretic technique
and the immunoassay method. They found negative
bias of immunoassay concentrations, the effect of
interference was not shown, and the number of
analyzed patients was small (N = 12). However, the
authors have noticed that suspected results can occur
only at very high concentrations of bALP (greater
than 140 U/L), in which case one should be careful
in interpreting the results. More than a decade ago, a
group of Slovenian authors analyzed the association
of activity and mass concentration of bALP measured
with immunoassay in pre and postmenopausal
women (15). The results of their study showed that
the activity and mass concentration of bALP
significantly correlated, both with each other and with
bone density parameters. However, in patients on
dialysis, the presence of uremic toxins and additional
bALP isoforms interfere with the adequate activity of
bALP, so interpretation of the results may be
problematic, especially in the case of high con cen -
trations of bALP, when measured using immunoassay
(16, 17).
The obtained CI of 95% of intercept and slope
in our study, using Passing-Bablock regression
analysis, indicate that there is no random and
systematic differences between the analyzed
methods, but revealed proportional differences in
measurement. This suggests that considerable efforts
should be performed to standardize bALP assays.
Besides, using analysis of residuals, as difference of
the observed OSTASE concentration with the value
predicted by the regression equation for the
corresponding bALP concentration, we found the
remaining variation after correcting for systematic
and proportional differences was minimal, as 95% of
the residuals lie in the interval ± 1.96 times the RSD.
Although, Passing Bablock residual plot revealed
good agreement for subgroups of patients with bALP
> 53 U/L, concordance coefficient for this subgroup
was not applicable, most likely because of the small
number of patients (N=9). The other two analyzed
subgroups (≤ 27 U/L and 27–53 U/L) represented
significant correlation and concordance coefficient.
However, Yessayan et al. (18) found, that compared
to iPTH, bALP was shown to be the optimal predictor
of biopsy findings with higher concentrations and an
optimal cut-off at 58 U/L. 
Limitation of this study is that we arbitrary
accepted electrophoresis method as referent method,
since this is originally method we routinely use in our
laboratory. We used initially recommended cut-off
values for bALP for low, normal and high bone
turnover. We are aware that these values are
debatable and that they may not be appropriate for
nowdays methods. In addition, we had insufficient
number of patients in subgroup with higher bALP
concentrations, although Passing Bablock residual
plot revealed good agreement for this subgroup. 
We can conclude, based on our results, that
immunoassay displays significant positive bias, in
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relation to electrophoresis, in the presence of other
alkaline phosphatase isoenzyme. Clinicians should be
aware of this phenomenon when they interpret bALP
results. It is important to conduct future studies that
include bone biopsy data, to determine adequate
clinical decision limits, for appropriate clinical utility of
bALP as a direct marker of bone metabolism.
Although immunoassays are increasingly used, as
fully automated methods, in a large number of
laboratories and become routine methods for bALP
determination, it should be beared in mind, besides
various interferences, also the heterogeneity of the
bALP itself, especially in HD patients.
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